CSL (CSLLY) Total Operating Expense: $2,318 Mil (TTM As of Dec. 2025)


CSLLY CSL Ltd CSLLY
73 GF Score
Price $19.98
GF Value $50.49
Valuation Significantly Undervalued
! 7 Warning Signs
View Full Analysis

What is CSL Total Operating Expense?

CSL CSLLY -2.30% 73 Total Operating Expense is $2,318 Mil as of Dec. 2025. GuruFocus rates CSLLY with a GF Score™ of 73/100 and a GF Value™ of $50.49 (Significantly Undervalued). The stock has 7 warning signs investors should review.

CSL's Total Operating Expense for the six months ended in Dec. 2025 was $2,318 Mil. CSL's Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was $2,318 Mil.

CSL Total Operating Expense Related Terms

CSL Total Operating Expense Historical Data

* Premium members only.

The historical data trend for CSL's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CSL Total Operating Expense Chart

CSL Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,208.60 3,347.40 4,606.00 4,797.00 4,992.00

CSL Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Jun25 Dec25
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,495.60 2,147.00 2,650.00 0.00 2,318.00
CSLLY
73GF Score
CSL Ltd CSLLY
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CSL Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $2,318 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $2,318 Mil mean?
CSL (CSLLY) has a Total Operating Expense of $2,318 Mil as of Dec. 2025. Total operating expense is the primary recurring expense associated with central operations. View historical data on CSL and its competitors.
Is CSL's Total Operating Expense too high?
CSL's current Total Operating Expense is $2,318 Mil. Overall, CSL has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CSL's Total Operating Expense compare to VRTX and REGN?
CSL's Total Operating Expense of $2,318 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on CSL and its competitors. CSL's current Total Operating Expense is $2,318 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSL stock overvalued right now?
Based on GuruFocus' analysis, CSL (CSLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $50.49, compared to a current price of $19.98 — trading 60.4% below its estimated fair value. The current Total Operating Expense is $2,318 Mil. CSL's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For CSL (CSLLY), the current Total Operating Expense is $2,318 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CSL (CSLLY) Overvalued in 2026?

Based on GuruFocus' analysis, CSL stock appears to be undervalued. The current stock price of $19.98 is trading 60.4% below its estimated GF Value™ of $50.49. GuruFocus considers CSL to be Significantly Undervalued.

Key valuation signals for CSLLY:

  • Total Operating Expense: $2,318 Mil
  • GF Value™: $50.49 vs. price of $19.98 (60.4% below fair value)
  • GF Score™: 73/100 with 7 warning signs

No single metric tells the full story. See the CSLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CSL Business Description

Address 655 Elizabeth Street, Melbourne, VIC, AUS, 3000
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
73GF Score

Get the complete analysis for CSLLY

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$19.98
Price
$50.49
GF Value